This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Semaglutide alleviates metabolic-linked liver disease in people with HIV

Semaglutide alleviates metabolic-linked liver disease in people with HIV

For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.

Jordan E. Lake, M.D., from UTHealth Houston, and colleagues designed a to examine the effect of semaglutide on magnetic resonance imaging-proton density fat fraction-quantified intrahepatic triglycerides (IHTG) in PWH and MASLD. Eligible participants were aged 18 years or older and had suppressed HIV-1 RNA while using antiretroviral therapy. The per-protocol analysis included 49 of 51 participants with central adiposity, or prediabetes, and steatotic liver disease.

The researchers observed clinically significant reductions in IHTG over 24 weeks. Overall, 29 and 58 percent of participants had complete resolution of MASLD and a relative reduction of IHTG of at least 30 percent, respectively. Anthropometric measurements, glucose regulation markers, and triglyceride concentrations also improved significantly. Semaglutide 1 mg weekly was tolerated by all participants. Grade 1 were the most common adverse events.

"In summary, semaglutide, 1 mg weekly, is an effective therapy for MASLD in PWH and shows evidence of broader cardiometabolic benefit," the authors write.

More information: Jordan E. Lake et al, The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV, Annals of Internal Medicine (2024). DOI: 10.7326/M23-3354

Journal information: Annals of Internal Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: Semaglutide alleviates metabolic-linked liver disease in people with HIV (2024, April 30) retrieved 13 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Semaglutide found to reduce severity of common liver disease in people with HIV


Feedback to editors